Seekyo Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Private

  • Employees
  • 8

Employees

  • Latest Deal Type
  • Later Stage VC

  • Investors
  • 7

Seekyo General Information

Description

Developer of a tumor microenvironment targeting smart chemotherapy designed to provide cancer patients with efficient treatment without adverse effects. The company's chemotherapy is designed with smart drugs that selectively target the microenvironment to safely transport powerful anti-cancer agents throughout the body, enabling cancer patients to get harmless, efficient, and selective cell treatment.

Contact Information

Website
www.seekyo-therapeutics.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Technopole Grand Poitiers Site CEI bat Téléport 1
  • 2, avenue Galilée BP 30153, Futuroscope Cedex
  • 86961 Poitiers
  • France
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • Technopole Grand Poitiers Site CEI bat Téléport 1
  • 2, avenue Galilée BP 30153, Futuroscope Cedex
  • 86961 Poitiers
  • France

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Seekyo Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC 01-Sep-2024 Completed Pre-Clinical Trials
5. Early Stage VC (Series A) 17-Mar-2021 Cancelled Pre-Clinical Trials
4. Early Stage VC (Series A) 17-Mar-2021 Completed Pre-Clinical Trials
3. Seed Round 20-Jan-2020 Completed Pre-Clinical Trials
2. Accelerator/Incubator Completed Pre-Clinical Trials
1. Accelerator/Incubator Completed Pre-Clinical Trials
To view Seekyo’s complete valuation and funding history, request access »

Seekyo Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Ordinary
Ordinary
To view Seekyo’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Seekyo Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a tumor microenvironment targeting smart chemotherapy designed to provide cancer patients with efficient tr
Drug Discovery
Poitiers, France
8 As of 2025

Marseille, France
 

Lyon, France
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Seekyo Competitors (2)

One of Seekyo’s 2 competitors is ImCheck Therapeutics, a Formerly VC-backed company based in Marseille, France.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
ImCheck Therapeutics Formerly VC-backed Marseille, France
MaaT Pharma Formerly VC-backed Lyon, France
You’re viewing 2 of 2 competitors. Get the full list »

Seekyo Patents

  • 8

    Total Documents Applications and Grants

  • Total Patents Families

  • 6

    Granted

  • 1

    Pending

  • Expiring in next 12 mo

Seekyo Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2020268749-A1 New therapeutic vectors and prodrugs for treating cancers Active 06-May-2019
AU-2020268749-B2 New therapeutic vectors and prodrugs for treating cancers Active 06-May-2019
CA-3139378-A1 New therapeutic vectors and prodrugs for treating cancers Pending 06-May-2019
EP-3965893-A1 New therapeutic vectors and prodrugs for treating cancers Active 06-May-2019
EP-3965893-B1 New therapeutic vectors and prodrugs for treating cancers Active 06-May-2019 C07D405/14
To view Seekyo’s complete patent history, request access »

Seekyo Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Seekyo Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds
Key Ventures Venture Capital Minority
Synergence Angel Group Minority
Bpifrance Sovereign Wealth Fund Minority
Investessor Angel Group Minority
WeLikeStartup Accelerator/Incubator Minority
You’re viewing 5 of 7 investors. Get the full list »

Ready to get started?

Request a free trial

Seekyo FAQs

  • When was Seekyo founded?

    Seekyo was founded in 2018.

  • Where is Seekyo headquartered?

    Seekyo is headquartered in Poitiers, France.

  • What is the size of Seekyo?

    Seekyo has 8 total employees.

  • What industry is Seekyo in?

    Seekyo’s primary industry is Drug Discovery.

  • Is Seekyo a private or public company?

    Seekyo is a Private company.

  • What is Seekyo’s current revenue?

    The current revenue for Seekyo is .

  • How much funding has Seekyo raised over time?

    Seekyo has raised $1.67M.

  • Who are Seekyo’s investors?

    Key Ventures, Synergence, Bpifrance, Investessor, and WeLikeStartup are 5 of 7 investors who have invested in Seekyo.

  • Who are Seekyo’s competitors?

    ImCheck Therapeutics and MaaT Pharma are competitors of Seekyo.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process